4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(1,3-thiazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]benzamide
C21H18F3N3O3S — CID 118045093
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(1,3-thiazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]benzamide
4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(1,3-thiazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]benzamide (PubChem CID 118045093) has the molecular formula C21H18F3N3O3S and a molecular weight of 449.45 g/mol. Its IUPAC name is 4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(1,3-thiazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]benzamide.
Molecular Properties
| Compound Name | 4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(1,3-thiazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]benzamide |
|---|---|
| PubChem CID | 118045093 |
| Molecular Formula | C21H18F3N3O3S |
| Molecular Weight | 449.45 g/mol |
| Exact Mass | 449.10 |
| IUPAC Name | 4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(1,3-thiazol-5-yl)-N-[4-(trifluoromethoxy)phenyl]benzamide |
| SMILES | O=C(Nc1ccc(OC(F)(F)F)cc1)c1ccc(N2CC[C@@H](O)C2)c(-c2cncs2)c1 |
| InChI | InChI=1S/C21H18F3N3O3S/c22-21(23,24)30-16-4-2-14(3-5-16)26-20(29)13-1-6-18(27-8-7-15(28)11-27)17(9-13)19-10-25-12-31-19/h1-6,9-10,12,15,28H,7-8,11H2,(H,26,29)/t15-/m1/s1 |
| InChIKey | ZSQFAKOJYJNADS-OAHLLOKOSA-N |
| XLogP | 4.53 |
| TPSA | 74.69 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 449.45 |
| LogP ≤ 5 | 4.53 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118045093 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.